Generex Biotechnology GNBT FDA Approval

September 10, 2009 - Shares of Generex Biotechnology Corp. (GNBT) are exploding as the company has received FDA Approval on their Buccal Insulin Product. GNBT stock is trading at $0.96 Up 41%.

Generex Announces USFDA Approval of Use of Company's Flagship Buccal Insulin Product, Generex Oral-lyn(TM), Under the USFDA'S Treatment Investigational New Drug (IND) Program

The FDA's Treatment IND program allows companies to provide early access to investigational drugs for patients with serious or life-threatening conditions for which there is no satisfactory alternative treatment. Drugs that are granted approval by the FDA for the Treatment IND program must demonstrate the prospect of efficacy through clinical testing. Full Article

Keep an eye on resistance at $1.14!

For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE